metabolic modulator comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Long-range omnidirectional transmitters would be very energy-intensive. Using directional or intermittent devices, each pointing in a different direction, would require much less energy. Type II or III civilizations might therefore be defined by something other than exponential energy consumption. The assumption of exponential energy consumption is certainly wrong, because if we analyze per capita energy consumption throughout human history, it forms a series of logistic curves with a saturation point for each technological innovation. Therefore, a steady state or limited growth is more likely. According to the principle of mediocrity, applied to the search for extraterrestrial civilizations by Sagan and Shklovskii in 1966 on the basis of John Richard Gott's calculations, civilizations more important than ours must be so rare that they do not have the possibility to dominate and be visible. Finally, research and listening programs in Harvard University and Buenos Aires (Horowitz and Sagan in 1993 or Lemarchand et al. in 1997) have not provided any scientific proof of the existence of artificial sources, neither in the Milky Way nor in nearby galaxies (M33, M81, the Whirlpool Galaxy or Centaurus A), or even in the Virgo cluster. For the British meteorologist Lewis Fry Richardson, author of a statistical study on mortality (published in Statistics of Deadly Quarrels, 1960), man's aggressiveness does not allow us to predict a life span that will allow humanity to reach more evolved stages.
Generalized HSD (G-HSD): Involves widespread joint hypermobility affecting multiple joints. Localized HSD (L-HSD): Limited to a few joints, without generalized involvement. Peripheral HSD (P-HSD): Affects joints in the hands and feet. Historical HSD (H-HSD): Diagnosed when there is a history of joint hypermobility that is no longer present, along with other symptoms. These classifications help in identifying the specific pattern and extent of joint hypermobility and in determining the appropriate management strategies.
=== Laboratory findings === Hormonal syndromes should be confirmed with laboratory testing. Laboratory findings in Cushing syndrome include increased serum glucose (blood sugar) and increased urine cortisol. Adrenal virilism is confirmed by the finding of an excess of serum androstenedione and dehydroepiandrosterone. Findings in Conn syndrome include low serum potassium, low plasma renin activity, and high serum aldosterone. Feminization is confirmed with the finding of excess serum estrogen.
general studies of protein structure and properties (because it is available in large quantities). studies of serpin structure and function (the fact that ovalbumin does not inhibit proteases means that by comparing its structure with that of inhibitory serpins, the structural characteristics required for inhibition can be determined). proteomics (chicken egg ovalbumin is commonly used as a molecular weight marker for calibrating electrophoresis gels). immunology (commonly used to stimulate an allergic reaction in test subjects; e.g., established model allergen for airway hyper-responsiveness, AHR). (For in vivo and in vitro studies based on ovalbumin it is important that the endotoxin content is less than 1 EU/mg.)
Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs. The disease can be either localized to the skin or involve other organs as well. Symptoms may include areas of thickened skin, stiffness, feeling tired, and poor blood flow to the fingers or toes with cold exposure. One form of the condition, known as CREST syndrome, classically results in calcium deposits, Raynaud's syndrome, esophageal problems, thickening of the skin of the fingers and toes, and areas of small, dilated blood vessels. The cause is unknown, but it may be due to an abnormal immune response. Risk factors include family history, certain genetic factors, and exposure to silica. The underlying mechanism involves the abnormal growth of connective tissue, which is believed to be the result of the immune system attacking healthy tissues. Diagnosis is based on symptoms, supported by a skin biopsy or blood tests. While no cure is known, treatment may improve symptoms. Medications used include corticosteroids, methotrexate, and non-steroidal anti-inflammatory drugs (NSAIDs). Outcome depends on the extent of disease. Those with localized disease generally have a normal life expectancy. In those with systemic disease, life expectancy can be affected, and this varies based on subtype. Death is often due to lung, gastrointestinal, or heart complications. About three per 100,000 people per year develop the systemic form. The condition most often begins in middle age. Women are more often affected than men.
Sources: en.wikipedia.org
By convention, the products form the numerator. However, the law of mass action is valid only for concerted one-step reactions that proceed through a single transition state and is not valid in general because rate equations do not, in general, follow the stoichiometry of the reaction as Guldberg and Waage had proposed (see, for example, nucleophilic aliphatic substitution by SN1 or reaction of hydrogen and bromine to form hydrogen bromide). Equality of forward and backward reaction rates, however, is a necessary condition for chemical equilibrium, though it is not sufficient to explain why equilibrium occurs. Despite the limitations of this derivation, the equilibrium constant for a reaction is indeed a constant, independent of the activities of the various species involved, though it does depend on temperature as observed by the van 't Hoff equation. Adding a catalyst will affect both the forward reaction and the reverse reaction in the same way and will not have an effect on the equilibrium constant. The catalyst will speed up both reactions thereby increasing the speed at which equilibrium is reached. Although the macroscopic equilibrium concentrations are constant in time, reactions do occur at the molecular level. For example, in the case of acetic acid dissolved in water and forming acetate and hydronium ions,
18 April to 31 December Operation Dan Thang 69 was conducted by the ARVN 22nd Division in Bình Định Province. The operation resulted in 507 PAVN/VC killed. Operation Dan Tien 33D was conducted by the ARVN 23rd Division in Quang Duc Province. The operation resulted in 746 PAVN/VC killed.
== Prizes and honours == 1997, 1999 Merit scholarship to study Medical Laboratory Technology at Institute of Medicine, Tribhuvan University 2005 Gallwas membership Grant, AACC 2005 and 2007 International travel grant, AACC 2006 Young Achievers Award 2007 International Travel Grant, Asian & Pacific Federation of Clinical Biochemistry (APFCB) 2008 and 2010 KNU Honors Scholarship for Graduation Study (MS and PHD) 2012 Featured member of AACC, interview published at AACC website 2013 KNU Best Publication Award 2014 KNU Cell-Matrix Research Institute Winter Seminar Award
=== Drowsiness === Tolerance to drowsiness usually develops over 5–7 days, but if troublesome, switching to an alternative opioid often helps. Certain opioids such as fentanyl, morphine and diamorphine (heroin) tend to be particularly sedating, while others such as oxycodone, codeine, and tilidine tend to produce comparatively less sedation, but individual patients responses can vary markedly and some degree of trial and error may be needed to find the most suitable drug for a particular patient. Otherwise, treatment with CNS stimulants is generally effective.
== History == The US Food and Drug Administration (FDA) approved eptinezumab based primarily on evidence from two clinical trials (Trial 1/NCT02559895 and Trial 2/NCT02974153) of 1741 participants with chronic or episodic migraine headaches. Trials were conducted at 212 sites in United States, Georgia, Russia, Ukraine and the European Union. The benefit and side effects of eptinezumab were evaluated in two clinical trials of adults aged 18 through 71 years of age with a history of migraine headaches. The trials had similar designs. Trial 1 enrolled participants with a history of episodic migraine headaches and Trial 2 enrolled participants with chronic migraine headaches. Participants were assigned to receive one of two doses of eptinezumab or placebo injections every three months for a total of twelve months in Trial 1, and for a total of 6 months in Trial 2. Neither the participants nor the health care providers knew which treatment was being given until the trial was completed. The benefit of eptinezumab in comparison to placebo was assessed based on the change in the number of migraine days per month during the first three-month treatment period.
Sources: en.wikipedia.org
== External links == Frontline: Dangerous prescriptions – Interview with Leo Lutwak, in which he discusses the side effects of fenfluramine (Pondimin), its successor dexfenfluramine (Redux), and the fen-phen combination. U.S. FDA fen-phen information Tellier P (November 2001). "Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts". Annales de Médecine Interne. 152 (7): 429–36. PMID 11965083.
The body normally gets the iron it requires from food. If a person consumes too little iron, or iron that is poorly absorbed (non-heme iron), they can become iron-deficient over time. Examples of iron-rich foods include meat, eggs, leafy green vegetables and iron-fortified foods. For proper growth and development, infants and children need dietary iron. For children, a high intake of cow's milk is associated with an increased risk of iron-deficiency anemia. Other risk factors (at least in toddlers) include low meat intake and low intake of iron-fortified products. The National Academy of Medicine updated Estimated Average Requirements (EAR) and Recommended Dietary Allowances (RDA) in 2001. The current EAR for iron for women ages 14–18 is 7.9 mg/day, 8.1 for ages 19–50, and 5.0 thereafter (post menopause). For men, the EAR is 6.0 mg/day for ages 19 and up. The RDA is 15.0 mg/day for women ages 15–18, 18.0 for 19–50, and 8.0 thereafter; for men, 8.0 mg/day for ages 19 and up. (Recommended Dietary Allowances are higher than Estimated Average Requirements so as to cover people with higher than average requirements.) The RDA for pregnancy is 27 mg/day, and during lactation, 9 mg/day. For children ages 1–3 years, it is 7 mg/day, 10 for ages 4–8, and 8 for ages 9–13. The European Food Safety Authority refers to the collective set of information as Dietary Reference Values, with Population Reference Intakes instead of RDAs, and Average Requirements instead of EARs.
=== June === 1 June – Aberdeen and Edinburgh become the latest Scottish cities to introduce low emission zones. 2 June – A memorial service is held at Southend Parish Church to mark the 30th anniversary of the 1994 RAF Chinook disaster in which 29 passengers and crew were killed. 3 June – The first 2024 general election leaders debate takes place in Scotland, with the leaders of Scotland's four main political parties taking part in a debate on STV. 5 June – Alba Party leader Alex Salmond confirms he will not stand in the general election, but instead plans to stand in the 2026 Scottish Parliament election in Banff and Buchan. 7 June – At the High Court in Edinburgh, council worker Michael Paterson admits to embezzling more than £1m from Aberdeen City Council while employed as a council tax and recovery team leader between 2006 and 2023. 9 June – The Sunday Mail reports allegations that Scottish Conservative leader Douglas Ross used Westminster expenses to travel in his role as a football linesman. 10 June – Douglas Ross announces his resignation as leader of the Scottish Conservatives, triggering a leadership election. Ross says he will also resign from Holyrood if he is re-elected to Westminster. 11 June – BBC Scotland airs an election debate featuring the leaders of Scotland's five main political parties: John Swinney (SNP), Douglas Ross (Scottish Conservatives), Anas Sarwar (Scottish Labour), Alex Cole-Hamilton (Scottish Liberal Democrats) and Lorna Slater (Scottish Greens).
A ligament is a type of fibrous connective tissue in the body that connects bones to other bones. It also connects flight feathers to bones, in dinosaurs and birds. All 30,000 species of amniotes (land animals with internal bones) have ligaments. It is also known as articular ligament, articular larua, fibrous ligament, or true ligament.
Creatine kinase U-type, mitochondrial, also called ubiquitous mitochondrial creatine kinase (uMtCK), is a protein that in humans encoded by CKMT1A gene. The nearby paralog, CKMT1B, encodes an identical (or nearly identical) protein, which currently shares a UniProt ID. CKMT1A catalyzes the reversible transfer of the γ-phosphate group of ATP to the guanidino group of Cr to yield ADP and PCr. The impairment of CKMT1A has been reported in ischaemia, cardiomyopathy, and neurodegenerative disorders. Overexpression of CKMT1A has been reported related with several tumors.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.